A double‐blind, placebo‐controlled study of patients undergoing IFN‐α therapy for malignant melanoma demonstrated that pretreatment with the antidepressant paroxetine was effective in preventing the development of major depression and was linked to improved adherence to IFN‐α therapy [120]. This evidence concerns the gene IFNA17 and melanoma.